Nanocarriers in Improved Heparin Delivery: Recent Updates

Author(s): Balak Das Kurmi, Pawan Tekchandani, Rishi Paliwal, Shivani Rai Paliwal

Journal Name: Current Pharmaceutical Design

Volume 21 , Issue 30 , 2015

Become EABM
Become Reviewer


Heparin, a well known drug for anticoagulant therapy and prophylaxis of deep vein thrombosis and coronary syndromes, is also involved in numerous pathological processes such as inflammation, immune cell migration, tumor cell metastasis, smooth muscle cell proliferation etc. Though heparin is a clinically used anticoagulant with minimal side effects and drug interactions, its clinical use is limited due to parenteral administration. Alternatively, noninvasive delivery approaches such as oral, nasal, pulmonary or transdermal route are being explored that may deal with problems associated with parenteral heparin without compromising therapeutic benefits. For the successful noninvasive delivery of such a large drug candidate, the biological and biochemical barriers must be overcome to achieve a clinically acceptable therapeutic advantage. Nanocarriers significantly improve the pharmacokinetics and clinical effectiveness of the loaded therapeutics by either protecting them from unfavorable bioenvironment or modifying their release at the target site. Novel carriers such as liposomes, nanoparticles, dendrimers etc. have been developed to improve the bioavailability of heparin through various routes of delivery. Overall, the present review provides complete insight to the research that has been carried out for heparin delivery through various routes.

Keywords: Anticoagulant, heparin, non-invasive delivery, nanocarrier, targeted drug delivery.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Page: [4509 - 4518]
Pages: 10
DOI: 10.2174/1381612821666150821112808
Price: $65

Article Metrics

PDF: 24